NRG-GY018

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Contact phone
517.364.9400
Principal investigator
Gordan Srkalovic, MD, PhD
Trial Category
Cancer
Trial SubCategory
Endometrial
Webform